English-language podcasts

Podcasts

BioCentury This Week

An episode can be the start of a conversation. Explore recent releases, share your thoughts, and meet through a ThinkMatch Roundtable.

Ask friends about this

Episodes to discuss

BioCentury This Week

Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds

29 min

J&J will pay $2.2 billion upfront to acquire Ollin (https://www.biocentury.com/article/661621), a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular edema. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the terms of the deal, what it says about NewCos as an exit path and Blackstone Life Sciences’ role in funding Phase III. The analysts also assess how a growing neoantigen vaccine pipeline (https://www.biocentury.com/article/661439) is testing the modality’s reach after Merck and Moderna’s Phase III win in melanoma, and the White House push (https://www.biocentury.com/article/661564) that has put Heidi Overton back in play ahead of the Nov. 18 Senate HELP Committee vote on her nomination as FDA commissioner. This episode of the BioCentury This Week podcast has been brought to you by Tigermed (https://www.tigermedgrp.com/). View full story: https://www.biocentury.com/article/661638 #NewCos #

Discuss this episode

BioCentury This Week

Ep. 397 - What the U.S. midterms mean for biopharma

29 min

Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner (https://www.biocentury.com/article/661541) and could open a narrow path to bipartisan drug pricing legislation (https://www.biocentury.com/article/661503). On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the results mean for FDA and HHS leadership, user fee negotiations, vaccine regulation, and the prospect of applying most-favored nation pricing to Medicare drug price negotiation. The analysts also unpack full Phase III data (https://www.biocentury.com/article/661524) showing pelacarsen failed across all subgroups and what it means for Lp(a) as a cardio target, highlight SITC abstracts (https://www.biocentury.com/article/661478) on localizing immunotherapy within solid tumors, and discuss argenx’s $550 million upfront buyout (https://www.biocentury.com/article/661512) of Unnatural Products. This episode of the BioCentury This Week podcast has be

Discuss this episode

BioCentury This Week

Ep. 396 - China’s first-order innovation

30 min

Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special edition of the BioCentury This Week podcast recorded live at the 13th BioCentury-BayHelix China Healthcare Summit in Shanghai, BioCentury’s Jeff Cranmer, Simone Fishburn and Josh Berlin are joined by Kali Therapeutics CEO Weihao Xu, Charles River’s Matthew Hewitt and Aerska CEO Jack O’Meara to discuss key themes from the event. The panel assesses what the COINS Act could mean for U.S. investment in China biotech and how investors may adapt, how China’s 30-day IND review and new investigator-initiated trial rules are reshaping clinical strategy, and what dealmaking reveals about the country’s growing first-in-class pipeline. They also preview BioCentury’s East-West Summit in Seoul (https://conferences.biocentury.com/east-west-summit), March 15-17. View full story: https://www.biocentury.com/article/661483 #Chin

Discuss this episode